drugset
Drugs / BMS-690514
last change Mar 2013 re-read 2 minutes ago

BMS-690514

also known as Bms 6690514 · EVRI

Small molecule targets EGFR, ERBB2, ERBB4 via inhibition

Developed for
cancer · non-small cell lung carcinoma · breast cancer
Investigated by
Bristol-Myers Squibb

Trials 6 · a red edge is where a trial was stopped

today NCT01167244 · Ph 2 NCT00743938 · Ph 2 NCT00578916 · Ph 1 NCT00516451 · Ph 1 NCT00420186 · Ph 1 NCT00329004 · Ph 1
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT00578916 Jan 2008 cancer Bristol-Myers Squibb Completed No outcome recorded
Phase 1 NCT00516451 Nov 2007 → Jul 2008 cancer Bristol-Myers Squibb Completed No outcome recorded
Phase 1 NCT00420186 Oct 2007 → Feb 2012 — Bristol-Myers Squibb Completed No outcome recorded
Phase 1 NCT00329004 Aug 2006 → Jul 2009 cancer Bristol-Myers Squibb Completed No outcome recorded
Phase 22 trials
Phase 2 NCT01167244 Aug 2010 → Apr 2011 non-small cell lung carcinoma Bristol-Myers Squibb Completed No outcome recorded
Phase 2 NCT00743938 Mar 2009 → Aug 2010 non-small cell lung carcinoma Bristol-Myers Squibb Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00479583 Comparator Sep 2007 → Apr 2010 cancer Bristol-Myers Squibb Completed No outcome recorded
Phase 21 trial
Phase 2 NCT01068704 Comparator Jun → Dec 2010 breast cancer Bristol-Myers Squibb Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as BMS-690514 “EVRI (BMS-690514)” NCT00578916 ↗
7

NCT00479583 ↗

NCT00329004 ↗

NCT01167244 ↗

NCT00420186 ↗

NCT00516451 ↗

NCT00743938 ↗

NCT01068704 ↗
Known as Bms 6690514 ChEMBL registry synonym — accepted as the source's own label CHEMBL3545396 ↗
Known as EVRI ClinicalTrials.gov intervention name — accepted as the source's own label NCT00578916 ↗
Action Inhibit “Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL3545396 ↗
2

“Receptor protein-tyrosine kinase erbB-4 inhibitor” CHEMBL3545396 ↗

“tyrosine kinase inhibitor of ErbB” PMID 22878519 ↗ Aug 2012
Modality Small molecule “oral tyrosine kinase inhibitor” PMID 23490650 ↗ Mar 2013
Route Oral “repeated oral administration” PMID 23490650 ↗ Mar 2013
Target EGFR “BMS-690514 is a potent, reversible oral inhibitor of epidermal growth factor receptor (EGFR/HER-1), HER-2 and -4, and vascular endothelial growth factor receptors (VEGFRs)-1 to...” PMID 23490650 ↗ Mar 2013
Target ERBB2 “Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL3545396 ↗
Target ERBB4 “Receptor protein-tyrosine kinase erbB-4 inhibitor” CHEMBL3545396 ↗